Triple

T5873377
Position Surface form Disambiguated ID Type / Status
Subject Committee for Advanced Therapies E130569 entity
Predicate worksWith P398 FINISHED
Object Pharmacovigilance Risk Assessment Committee E130559 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmacovigilance Risk Assessment Committee | Statement: [Committee for Advanced Therapies, worksWith, Pharmacovigilance Risk Assessment Committee]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Pharmacovigilance Risk Assessment Committee
Context triple: [Committee for Advanced Therapies, worksWith, Pharmacovigilance Risk Assessment Committee]
  • A. Pharmacovigilance Risk Assessment Committee
    The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
  • B. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency chosen
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • C. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • D. Centre for Pharmacovigilance
    The Centre for Pharmacovigilance is a Norwegian public health unit responsible for monitoring, assessing, and improving the safety of medicines and vaccines in Norway.
  • E. Committee for Medicinal Products for Human Use
    The Committee for Medicinal Products for Human Use is the European Medicines Agency’s expert body responsible for evaluating and providing scientific opinions on the safety, quality, and efficacy of medicines for human use in the European Union.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c0085047dc8190af24e311edad3c07 completed March 22, 2026, 3:18 p.m.
NER Named-entity recognition batch_69c035f99b788190b5b06d83b9499bfa completed March 22, 2026, 6:33 p.m.
NED1 Entity disambiguation (via context triple) batch_69c0bfeb7b0881909ca26e2d8110edda completed March 23, 2026, 4:22 a.m.
Created at: March 22, 2026, 3:57 p.m.